PT Pyridam Farma Tbk (IDX: PYFA)
Health Care · Pharmaceuticals · ID
Rp236.00
+11.32% today · -60.0% 1Y
PT Pyridam Farma Tbk (IDX: PYFA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $150.24M and employs 2,463 people.
Over the last twelve months the share price has lost 60.0%, trading between 158.00 and 700.00.
Tweenvest scores PT Pyridam Farma Tbk across four factors: quality 38/100, value 44/100, growth 100/100. Its strongest factor is growth.
PYFA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $150.24M
- Revenue (TTM)
- $167.28M
- P/E
- —
- EPS
- -29.84
- Dividend yield
- —
- Beta (5Y)
- 0.76
- 52-week high
- Rp700.00
- 52-week low
- Rp158.00
- Avg volume (3M)
- —
- Shares outstanding
- 11.24B
- Employees
- 2,463
- Next earnings
- —
About PT Pyridam Farma Tbk
PT Pyridam Farma Tbk, an Indonesian-based enterprise, specializes in the development, production, and distribution of a broad spectrum of health-related products. Its offerings encompass pharmaceuticals, antibiotics, essential vitamins, dietary supplements, and traditional herbal remedies. The company's operations are divided into two main segments: Pharmaceutical Products and Contract Manufacturing Services, and Medical Device Products. Within its medical device division, the firm provides a variety of instruments and consumables. These include clinical waste management items, collection swabs and tubes, innerbox DCA, KF94 masks, parafilm, PCR extraction kits and their accompanying machinery, specimen bags, sterile containers, and tube stoppers. Furthermore, PT Pyridam Farma markets a diverse collection of skincare products, such as Arosa gel, A-Stark Gel, Hymen gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb gel. Its pharmaceutical portfolio addresses numerous therapeutic areas, including digestive and metabolic health, blood and blood-forming organ conditions, cardiovascular disorders, dermatological ailments, genitourinary system and sex hormone regulation, systemic corticosteroids, systemic antibacterial treatments, sensory organ issues, as well as musculoskeletal, nervous, and respiratory system conditions. Beyond medicinal lines, the company also develops and sells dietary supplements and preventive consumer health items, notably energy drinks and various healthy ready-to-consume beverages. A key area of its strategic focus involves conducting extensive research and development in biotechnology, life sciences, and medical science. Established in 1976, PT Pyridam Farma Tbk is headquartered in Jakarta, Indonesia.
- ISIN
- ID1000075609
- Founded
- 1976
- Listed since
- Oct 16, 2001
- Exchange
- Indonesia Stock Exchange
- Currency
- IDR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.